Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$514.00K$514.00K−44.6% vs Q1 2019 Net Income-$8.40M-$8.40MN/M vs Q1 2019 EPS Diluted-$0.06-$0.06N/M vs Q1 2019 Gross Profit$420,000−51.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow-$5,026,000N/M Free Cash Flowderived-$5,036,000N/M Margins · derivedGross margin81.7%−11.0 pt vs Q1 2019
Operating margin-1447.1%−72.0 pt vs Q1 2019
Net margin-1634.0%
ended Mar 31, 2020 · filed May 7, 2020 · 37 d after period end